Total Funding
83
38
Total FundingPost-IPO Equity raised
Growth Score
-7 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
261355
Vicapsys is a biotech company developing treatments for diabetes and other conditions.
- Federico Pier: CEOa and Executive Chairman
About the Company
Vicapsys is a biotech company developing treatments for diabetes and other conditions. It focuses on leveraging natural pathways in a localized manner in order to achieve beneficial therapies without systemic negative consequences. At the core of Vicapsys technology is a pleiotropic cytokine, CXCL12 that can be optimally formulated to achieve
therapeutic outcomes in different indications. It is currently focused on curing Type 1 diabetes through the long-term survival of transplanted islet cells using a formulation that inhibits the development of the foreign body response and immune protection.
